Clinical Trial Update: Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating autologous CD22 CAR T cells in adults with recurrent or refractory B-cell malignancies has completed enrollment. Results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma Grade 3b

Drugs mentioned

• Autologous CD22 CAR-T cells (CD22-directed CAR-T cells)

Snippet

Sponsor: Matthew Frank | Conditions: B-ALL, B-cell Non Hodgkin Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2026-03-30